ARS Pharmaceuticals(SPRY) Newsfilter·2025-01-21 13:00Core Points - ARS Pharmaceuticals has launched the neffyinSchools program to provide eligible K-12 schools in the U.S. with free access to neffy® (epinephrine nasal spray) for emergency use [1][5] - The program aims to ensure that schools are prepared to handle severe allergic reactions, which can occur unexpectedly [2][3] - neffy 2 mg is approved for treating Type I allergic reactions, including anaphylaxis, in individuals weighing 30 kg (66 lbs) or more [1][6] Group 1: Program Details - Eligible schools will receive two cartons (four single-use doses) of neffy 2 mg at no cost, with replacement doses available when used or expired [1][5] - The program is specifically for undesignated use, meaning schools must ensure compliance with local laws regarding epinephrine stocking and administration [5][3] - A supplemental NDA for a 1 mg dose of neffy has been granted priority review by the FDA, with a PDUFA date set for March 6, 2025 [5] Group 2: Importance of the Program - The program addresses the critical need for immediate access to epinephrine in schools, as one-quarter of anaphylactic reactions occur in students with previously undiagnosed allergies [3][15] - Approximately 1 in 20 school-aged children are affected by food allergies, highlighting the necessity for schools to be equipped for emergencies [3][15] - The neffyinSchools program is expected to enhance the safety and preparedness of schools in managing anaphylaxis [2][3] Group 3: Company Commitment - ARS Pharmaceuticals is dedicated to making neffy freely available to eligible schools, emphasizing the importance of life-saving epinephrine in emergency situations [3][16] - The company aims to improve the accessibility and administration of epinephrine, addressing common barriers associated with traditional autoinjectors [15][16] - ARS Pharmaceuticals will host a webinar for school nurses and administrators to provide information about the neffyinSchools program [3]